Skip to content
Screener

Ultragenyx Pharmaceutical RARE Gross Profit

Discontinued — last reported Q2 '19

Gross Profit at other companies

Eli Lilly logo
Eli LillyLLY
$19.71B+50.3%
Amgen logo
AmgenAMGN
$7.24B+17.4%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$265.21M-40.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$38.14M+182%
Moderna logo
ModernaMRNA
$52M+126%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$3.51M—

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%—
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

$24.1Mtotal revenue−$766.0Ktotal cost of revenue=$23.38M

The source filing: Ultragenyx Pharmaceutical’s 10-K, filed February 12, 2021. Open the filing →

Filed
Feb 11, 2021, 6:37 PM EST
Fiscal year
FY2020
Accession
0001564590-21-005610

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.